Cero Therapeutics presents preclinical data on CER-1236

CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models. The data were presented in a poster at the Society for Immunology of Cancer 2024 conference held in Houston November 6-10, 2024. Interim CEO Chris Ehrlich commented, “We have long contended that CER-1236 has application in multiple cancer types. While we await the opportunity to introduce our compound into the clinic for AML, we continue to see other models in which there is utility and minimal-to-no toxicity. These data are of particular interest as the Company plans to apply for Orphan designation at the appropriate time in clinical development. Regardless, these data are further confirmation that our approach has enormous potential to go beyond some of the limitations of current chemotherapy approaches.” The study, titled, “TIM-4 Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,” investigators assessed CER-1236 on the immune receptor TIM-4-L in ovarian cancer cell lines. Results demonstrated that following the introduction of CER-1236 on these cell lines, TIM-4-L increased, which then responded with the killing of the cancer cells, but with no observed toxicity to healthy cells. The study further showed CER-1236 specificity to TIM-L-4, which investigators concluded that combined with the lack of association with clinically relevant toxicity, may make the compound an attractive option for treating ovarian cancer.